Table 1.

Period, amplitude and damping rate analyses of bioluminescence patterns following various treatments

Cell type/tissue	Treatment	Period (h)	Amplitude (counts/s)	Damping rate (d)
Period1-luciferase rat-1 fibroblasts	Control	24.23 ± 0.17	188.11 ± 21.20	1.72 ± 0.23	Fig. 2
	DMSO	24.28 ± 0.20 ns	285.06 ± 12.52*	1.57 ± 0.09 ns
	SP600125 30μM	31.48 ± 0.07***	260.27 ± 50.62 ns	1.30 ± 0.05 ns
	SP, negative control 30μM	24.83 ± 0.38 ns	181.85 ± 21.47 ns	2.06 ± 0.35 ns
Mouse Period1-luciferase SCN	Control	24.63 ± 0.59	234.81 ± 84.02	1.22 ± 0.25	Fig. 5A
	SP600125 30μM	32.45 ± 0.99**	197.75 ± 119.46 ns	1.05 ± 0.23 ns
Mouse Period2Luciferase SCN	Control	24.10 ± 0.25	150.74 ± 55.86	4.12 ± 1.16	Fig. 5A
	SP600125 30μM	32.96 ± 1.19*	75.35 ± 10.11 ns	2.93 ± 0.48 ns
Mouse Period1-luciferase pineal gland	Control	23.55 ± 0.25	44.51 ± 12.59	2.60 ± 0.57	Fig. 5B
	SP600125 30μM	32.83 ± 1.04**	330.23 ± 138.32 ns	1.01 ± 0.03 ns
Mouse Period2Luciferase pineal gland	Control	23.87 ± 0.13	79.56 ± 20.47	1.70 ± 0.33	Fig. 5B
	SP600125 30μM	35.35 ± 0.93***	87.22 ± 19.68 ns	1.73 ± 0.09 ns
Mouse Period1-luciferase lungs	Control	24.63 ± 0.27	175.35 ± 48.60	1.88 ± 0.17	Fig. 6A
	SP600125 30μM	30.56 ± 1.45*	151.03 ± 68.12 ns	2.80 ± 0.86 ns
Mouse Period2Luciferase lungs	Control	23.65 ± 0.12	33.29 ± 19.64	3.29 ± 0.55	Fig. 6A
	SP600125 30μM	32.78 ± 1.34***	63.44 ± 23.26 ns	1.92 ± 0.16 ns
Mouse Period1-luciferase kidneys	Control	24.54 ± 0.14	15.52 ± 4.42	3.97 ± 0.53	Fig. 6B
	SP600125 30μM	N/A	N/A	N/A
Mouse Period2Luciferase kidneys	Control	24.16 ± 0.20	258.96 ± 201.11	1.34 ± 0.25	Fig. 6B
	SP600125 30μM	25.46 ± 0.78 ns	21.78 ± 10.92 ns	1.40 ± 0.15 ns
Period1-luciferase rat-1 fibroblasts	Control	23.98 ± 0.12	141.60 ± 19.99	1.70 ± 0.14	Fig. 7A
	Valproic acid 1mM	23.35 ± 0.17*	503.25 ± 119.58*	1.59 ± 0.44 ns

N/A, analysis not possible due to a lack of rhythmicity; ns, not significant; SP, SP600126.

^*p<0.05.

^**p<0.005.

^***p<0.0005.